Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Eleni Andreopoulou, ASCO 2019 – Immunotherapy in breast cancer (Part 1)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 11th 2019

Editorial Board member, Eleni Andreopoulou, spoke to us at the 2019 ASCO annual meeting about the advances made in immunotherapy for the treatment of breast cancer.

In Part 1 Eleni discusses the rationale and evidence that supports the use of immune checkpoint inhibitors.

Questions

1. What is the rationale for the use of immune checkpoint inhibitors in breast cancer, which has historically been viewed as not immunogenic? (0:04)
2. What clinical evidence supports the use of immune checkpoint inhibitors in early stage and metastatic breast cancer? (1:28)

Speaker disclosure: Eleni Andreopoulou has nothing to disclosure in relation to this video interview.

Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup